Screen 100-1000x more VHH antibody sequences with the largest libraries on the market
Combining the largest and most diverse synthetic VHH libraries available with our proprietary, cell-free CIS display technology means that these uniquely vast libraries can reach their full potential in under half the time of traditional immunisation methods.
Tools for ADC drug discovery – screening VHHs with pre-engineered C-terminal cysteine handles
Isogenica developed a screening approach using pre-engineered C-terminal Cysteine handles. VHHs expressed well in this format and formed spontaneous stable dimers. This approach can now be applied to future projects which require VHH antibody conjugation for ADC and other applications.
Passionate about patient outcomes
With a shared passion for discovery and a collaborative spirit, our team works to advance the field and support the development of ground-breaking therapies. Get to know the faces behind our pioneering work and see why we are trusted partners in the journey from concept to cure.
Connect with us
Join us Antibody Engineering & Therapeutics Europe June 10–12, 2025.
Connect with Isogenica at Antibody Engineering & Therapeutics Europe in Basel, June 10-12, 2025. Meet our team at Europe's leading...
Stay up to date
Isogenica and Cube Biotech Unite to Accelerate GPCR Therapeutics
Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of the most complex challenges in drug discovery: G protein-coupled receptors (GPCRs).
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions
Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.
Isogenica is proud to announce two new Non-Executive Directors
Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.